by Noah Oshry | May 27, 2026
May 27, 2026 (CAMBRIDGE, MA) – Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored immunotherapy to deliver better outcomes for people with cancer and other serious diseases, announced two poster presentations will be featured at the 2026...
by Noah Oshry | May 11, 2026
May 11, 2026 (CAMBRIDGE, MA) – Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored immunotherapy to deliver better outcomes for people with cancer and other serious diseases, announced a poster presentation will be featured at the 2026 PEGS...
by Noah Oshry | Apr 16, 2026
April 16, 2026 (CAMBRIDGE, MA) – Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored immunotherapy to deliver better outcomes for people with cancer and other serious diseases, announced two poster presentations will be featured at the...
by ankyratx1dev | Feb 18, 2026
Ankyra Therapeutics Presents First Preclinical Data on ANK-203, a Novel CD137-Anchored Immunotherapy Candidate, in Oral Session at AACR IO ANK-203 is a first-in-class anchored immunotherapy designed to unlock the full therapeutic potential of monoclonal antibody...
by ankyratx1dev | Dec 15, 2025
Ankyra appoints Sailaja Battula, PhD as chief scientific officer (CSO) December 15, 2025 (Cambridge, MA) – Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored drug conjugate technology for cancer and other diseases, today announced Sailaja...
